CEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
CEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course. / Plage, Henning; Furlano, Kira; Neymeyer, Jörg; Weinberger, Sarah; Gerdes, Benedikt; Hubatsch, Mandy; Ralla, Bernhard; Franz, Antonia; Fendler, Annika; de Martino, Michela; Roßner, Florian; Schallenberg, Simon; Elezkurtaj, Sefer; Kluth, Martina; Lennartz, Maximilian; Blessin, Niclas C.; Marx, Andreas H.; Samtleben, Henrik; Fisch, Margit; Rink, Michael; Kaczmarek, Krystian; Ecke, Thorsten; Hallmann, Steffen; Koch, Stefan; Adamini, Nico; Minner, Sarah; Simon, Ronald; Sauter, Guido; Weischenfeldt, Joachim; Klatte, Tobias; Schlomm, Thorsten; Horst, David; Zecha, Henrik; Slojewski, Marcin.
In: BJUI Compass, Vol. 5, No. 6, 2024, p. 585–592.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - CEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course
AU - Plage, Henning
AU - Furlano, Kira
AU - Neymeyer, Jörg
AU - Weinberger, Sarah
AU - Gerdes, Benedikt
AU - Hubatsch, Mandy
AU - Ralla, Bernhard
AU - Franz, Antonia
AU - Fendler, Annika
AU - de Martino, Michela
AU - Roßner, Florian
AU - Schallenberg, Simon
AU - Elezkurtaj, Sefer
AU - Kluth, Martina
AU - Lennartz, Maximilian
AU - Blessin, Niclas C.
AU - Marx, Andreas H.
AU - Samtleben, Henrik
AU - Fisch, Margit
AU - Rink, Michael
AU - Kaczmarek, Krystian
AU - Ecke, Thorsten
AU - Hallmann, Steffen
AU - Koch, Stefan
AU - Adamini, Nico
AU - Minner, Sarah
AU - Simon, Ronald
AU - Sauter, Guido
AU - Weischenfeldt, Joachim
AU - Klatte, Tobias
AU - Schlomm, Thorsten
AU - Horst, David
AU - Zecha, Henrik
AU - Slojewski, Marcin
N1 - Publisher Copyright: © 2024 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.
PY - 2024
Y1 - 2024
N2 - Objectives: Carcinoembryonic antigen (CEA) is a cell surface glycoprotein that represents a promising therapeutic target. Serum measurement of shedded CEA can be utilized for monitoring of cancer patients. Material and Methods: To evaluate the potential clinical significance of CEA expression in urothelial bladder neoplasms, CEA was analysed by immunohistochemistry in more than 2500 urothelial bladder carcinomas in a tissue microarray format. Results: CEA staining was largely absent in normal urothelial cells but was observed in 30.4% of urothelial bladder carcinomas including 406 (16.7%) with weak, 140 (5.8%) with moderate, and 192 (7.9%) with strong staining. CEA positivity occurred in 10.9% of 411 pTaG2 low-grade, 32.0% of 178 pTaG2 high-grade, and 43.0% of 93 pTaG3 tumours (p < 0.0001). In 1335 pT2–4 carcinomas, CEA positivity (34.1%) was lower than in pTaG3 tumours. Within pT2–4 carcinomas, CEA staining was unrelated to pT, pN, grade, L-status, V-status, overall survival, recurrence free survival, and cancer specific survival (p > 0.25). Conclusion: CEA increases markedly with grade progression in pTa tumours, and expression occurs in a significant fraction of pT2–4 urothelial bladder carcinomas. The high rate of CEA positivity in pT2–4 carcinomas offers the opportunity of using CEA serum measurement for monitoring the clinical course of these cancers. Moreover, CEA positive urothelial carcinomas are candidates for a treatment by targeted anti-CEA drugs.
AB - Objectives: Carcinoembryonic antigen (CEA) is a cell surface glycoprotein that represents a promising therapeutic target. Serum measurement of shedded CEA can be utilized for monitoring of cancer patients. Material and Methods: To evaluate the potential clinical significance of CEA expression in urothelial bladder neoplasms, CEA was analysed by immunohistochemistry in more than 2500 urothelial bladder carcinomas in a tissue microarray format. Results: CEA staining was largely absent in normal urothelial cells but was observed in 30.4% of urothelial bladder carcinomas including 406 (16.7%) with weak, 140 (5.8%) with moderate, and 192 (7.9%) with strong staining. CEA positivity occurred in 10.9% of 411 pTaG2 low-grade, 32.0% of 178 pTaG2 high-grade, and 43.0% of 93 pTaG3 tumours (p < 0.0001). In 1335 pT2–4 carcinomas, CEA positivity (34.1%) was lower than in pTaG3 tumours. Within pT2–4 carcinomas, CEA staining was unrelated to pT, pN, grade, L-status, V-status, overall survival, recurrence free survival, and cancer specific survival (p > 0.25). Conclusion: CEA increases markedly with grade progression in pTa tumours, and expression occurs in a significant fraction of pT2–4 urothelial bladder carcinomas. The high rate of CEA positivity in pT2–4 carcinomas offers the opportunity of using CEA serum measurement for monitoring the clinical course of these cancers. Moreover, CEA positive urothelial carcinomas are candidates for a treatment by targeted anti-CEA drugs.
KW - bladder cancer
KW - CEA
KW - CEACAM5
KW - immunohistochemistry
KW - prognosis
KW - tissue microarray
U2 - 10.1002/bco2.354
DO - 10.1002/bco2.354
M3 - Journal article
C2 - 38873357
AN - SCOPUS:85189794938
VL - 5
SP - 585
EP - 592
JO - BJUI Compass
JF - BJUI Compass
SN - 2688-4526
IS - 6
ER -
ID: 389410479